[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dogwood Therapeutics Inc (DWTX)

Dogwood Therapeutics Inc (DWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,543
  • Shares Outstanding, K 33,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,260 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.13
  • Low Estimate $-0.13
  • Prior Year $-1.99
  • Growth Rate Est. (year over year) +93.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3350 +38.58%
on 07/20/26
1.8900 -2.12%
on 08/04/26
+0.4300 (+30.28%)
since 07/10/26
3-Month
1.2800 +44.53%
on 07/07/26
1.9800 -6.57%
on 05/14/26
+0.1600 (+9.47%)
since 05/11/26
52-Week
1.2800 +44.53%
on 07/07/26
9.5000 -80.53%
on 09/29/25
-2.9201 (-61.22%)
since 08/11/25

Most Recent Stories

More News
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Announces First Quarter 2026 Financial Results

-  Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy,...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood  licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

 - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood...

DWTX : 1.8300 (-2.73%)
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement   Offerings priced at-the-market under Nasdaq rules   ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE)...

DWTX : 1.8300 (-2.73%)

Business Summary

Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA.

See More

Key Turning Points

3rd Resistance Point 1.9967
2nd Resistance Point 1.9233
1st Resistance Point 1.8767
Last Price 1.8300
1st Support Level 1.7567
2nd Support Level 1.6833
3rd Support Level 1.6367

See More

52-Week High 9.5000
Fibonacci 61.8% 6.3600
Fibonacci 50% 5.3900
Fibonacci 38.2% 4.4200
Last Price 1.8300
52-Week Low 1.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.